newsfilter
← Latest News
GlobeNewswire·

Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020...